Genomic landscape and potential therapeutic targets in alpha-fetoprotein-producing gastric cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Alpha-fetoprotein-producing gastric carcinoma (AFPGC) is a rare cancer. This study identifies key diagnostic markers, frequent mutations like TP53, and actionable targets, improving diagnosis and treatment strategies for AFPGC.
Area Of Science
- Oncology
- Gastroenterology
- Molecular Pathology
Background
- Alpha-fetoprotein-producing gastric carcinoma (AFPGC) is a rare and aggressive subtype of gastric cancer.
- Understanding its clinicopathological, immunophenotypic, and molecular features is crucial for developing effective therapeutic strategies.
Purpose Of The Study
- To comprehensively analyze the characteristics of AFPGC.
- To identify potential diagnostic markers, therapeutic targets, and prognostic factors for AFPGC.
Main Methods
- Retrospective cohort study of 91 patients with AFPGC.
- Utilized immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS).
Main Results
- AFPGC is more common in males, often found in the cardia and antrum.
- IHC markers (AFP, GPC3, SALL4, CD10, CDX-2, ATBF1) aid diagnosis.
- TP53 hypermutation was frequent; CCNE1, ERBB2, and EGFR alterations were common, suggesting targeted therapy benefits.
- LRP1B and ARID1A were identified as prognostic factors for OS and DFS, respectively.
Conclusions
- This study provides insights into AFPGC characteristics, aiding diagnosis and identifying therapeutic targets.
- Findings support the potential benefit of targeted therapies and highlight prognostic factors for improved patient management.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
